Gist-Brocades N.v.

Robert W Van Leen

Lambertus C Dorssers

Hans Pannekoek

Yvonne J Vos

Albert J Van Ooyen

Gerard Wagemaker

Martinus Philippus Verbeet

Maria L Persoon

Biologically active deletion and substitution mutants of hIL-3 are provided. Preferred mutants are those having one or more deletions at the N-terminus (amino acids 1-14) and/or the C-terminus (amino acids 116-133, 120-130 and/or 130-133). Preferred substitution mutants include Cys.sup.16 .fwdarw.Ala.sup.16 and/or Cys.sup.84 .fwdarw.Ala.sup.84, Glu.sup.50 .fwdarw.Lys.sup.50 and Lys.sup.79 .fwdarw.Glu.sup.79. These mutants can be used to formulate pharmaceutical compositions. Also disclosed are antibodies directed against specific epitopes localized between amino acids 29 and 54.

N- and C-terminal truncation and deletion mutants of human interleukin-3

Methods are provided for improved production of hIL-3 either in glycosylated form from mammalian and yeast cells or in unglycosylated form from prokaryotes. Recombinantly produced human IL-3 is purified in a series of steps, initially employing hydrophobic interaction, followed by ion exchange chromatography and gel filtration.

Expression and purification of human interleukin-3 and muteins thereof

Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have sequences substantially similar to portions of naturally occuring Factor VIII. The polypeptides find use in treatment of Hemophilia A.

Proteins with factor VIII activity: process for their preparation using

Growing community of inventors

Nijmegen, Netherlands

Robert W Van Leen